PMID- 18454680
OWN - NLM
STAT- MEDLINE
DCOM- 20080730
LR  - 20211020
IS  - 0022-1899 (Print)
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 198
IP  - 1
DP  - 2008 Jul 1
TI  - Genetic basis for adverse events after smallpox vaccination.
PG  - 16-22
LID - 10.1086/588670 [doi]
AB  - Identifying genetic factors associated with the development of adverse events 
      might allow screening before vaccinia virus administration. Two independent 
      clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in 
      healthy, vaccinia virus-naive adult volunteers. Volunteers were assessed 
      repeatedly for local and systemic adverse events (AEs) associated with the 
      receipt of vaccine and underwent genotyping for 1,442 singlenucleotide 
      polymorphisms (SNPs). In the first study, 36 SNPs in 26 genes were associated 
      with systemic AEs (P <or= .05); these 26 genes were tested in the second study. 
      In the final analysis, 3 SNPs were consistently associated with AEs in both 
      studies. The presence of a nonsynonymous SNP in the methylenetetrahydrofolate 
      reductase (MTHFR)gene was associated with the risk ofAEin both trials (odds ratio 
      [OR], 2.3 [95% confidence interval CI, 1.1-5.2] [P = .04] and OR, 4.1 [95% CI, 
      1.4 -11.4] [P<.01]). Two SNPs in the interferon regulatory factor-1 (IRF1) gene 
      were associated with the risk of AE in both sample sets (OR, 3.2 [95% CI, 
      1.1-9.8] [P = .03] andOR, 3.0 [95% CI, 1.1- 8.3] [P = .03]). Genetic 
      polymorphisms in genes expressing an enzyme previously associated with adverse 
      reactions to a variety of pharmacologic agents (MTHFR) and an immunological 
      transcription factor (IRF1) were associated with AEs after smallpox vaccination 
      in 2 independent study samples.
FAU - Reif, David M
AU  - Reif DM
AD  - Computational Genetics Laboratory, Dartmouth Medical School, Lebanon, New 
      Hampshire, USA.
FAU - McKinney, Brett A
AU  - McKinney BA
FAU - Motsinger, Alison A
AU  - Motsinger AA
FAU - Chanock, Stephen J
AU  - Chanock SJ
FAU - Edwards, Kathryn M
AU  - Edwards KM
FAU - Rock, Michael T
AU  - Rock MT
FAU - Moore, Jason H
AU  - Moore JH
FAU - Crowe, James E
AU  - Crowe JE
LA  - eng
GR  - R21-AI-59365/AI/NIAID NIH HHS/United States
GR  - R01-AI-59694/AI/NIAID NIH HHS/United States
GR  - T32 GM062758/GM/NIGMS NIH HHS/United States
GR  - R01 GM-62758/GM/NIGMS NIH HHS/United States
GR  - K25-AI-64625/AI/NIAID NIH HHS/United States
GR  - N01-AI-25462/AI/NIAID NIH HHS/United States
GR  - R21 AI059365/AI/NIAID NIH HHS/United States
GR  - M01 RR-00095/RR/NCRR NIH HHS/United States
GR  - R01 AI059694/AI/NIAID NIH HHS/United States
GR  - K25 AI064625/AI/NIAID NIH HHS/United States
GR  - R01 AI059694-05/AI/NIAID NIH HHS/United States
GR  - N01AI25462/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Interferon Regulatory Factor-1)
RN  - 0 (Smallpox Vaccine)
RN  - 207137-56-2 (Interleukin-4)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
EIN - J Infect Dis. 2008 Sep 1;198(5):796
CIN - J Infect Dis. 2008 Jul 1;198(1):4-5. PMID: 18454681
CIN - J Infect Dis. 2020 Sep 14;222(8):1413-1414. PMID: 31158294
MH  - Adult
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Interferon Regulatory Factor-1/genetics
MH  - Interleukin-4/genetics
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/genetics
MH  - *Polymorphism, Single Nucleotide
MH  - Smallpox Vaccine/*adverse effects
MH  - Vaccination/*adverse effects
PMC - PMC2746083
MID - NIHMS107979
COIS- CONFLICT OF INTEREST STATEMENT: Financial Disclosures: Dr. Crowe reported being 
      the recipient of research funding from Sanofi-Aventis, Vaxgen, and a joint STTR 
      award with Mapp Pharmaceuticals. He has consulted for MedImmune, Vaxin, Evogenix, 
      Symphogen, and Syngenta. Dr. Edwards reported being the recipient of research 
      funding from Sanofi-Aventis, MedImmune, Vaxgen, Merck, and Wyeth. She has 
      consulted for MedImmune and Wyeth. No other authors reported disclosures. Role of 
      the Sponsor: The funding organizations played no role in design and conduct of 
      the study; collection, management, analysis, and interpretation of the data; or 
      in the preparation, review, or approval of the manuscript.
EDAT- 2008/05/06 09:00
MHDA- 2008/07/31 09:00
PMCR- 2009/09/17
CRDT- 2008/05/06 09:00
PHST- 2008/05/06 09:00 [pubmed]
PHST- 2008/07/31 09:00 [medline]
PHST- 2008/05/06 09:00 [entrez]
PHST- 2009/09/17 00:00 [pmc-release]
AID - 10.1086/588670 [doi]
PST - ppublish
SO  - J Infect Dis. 2008 Jul 1;198(1):16-22. doi: 10.1086/588670.